News & Media

Sep 14 / 2021

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Jul 06 / 2021

Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Jul 05 / 2021

Hemostemix Announces Warrant Repricing and Extension
Jun 21 / 2021

Peter Lacey Increases his Investment in Hemostemix Inc.
Jun 11 / 2021

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
May 29 / 2021

Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
May 29 / 2021

Hemostemix Announces that, due to the COVID-19 Pandemic, the Annual and Special Meeting will only be held via Zoom and Shareholders are requested to follow the meeting instructions mailed to the Shareholders of Record
May 25 / 2021

Hemostemix to Present at the Emerging Growth Conference
May 10 / 2021

HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT
May 06 / 2021

Hemostemix Announces Warrant Repricing and Extension
Apr 30 / 2021

Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
Apr 26 / 2021

Hemostemix Reprices and Amends the Terms of its Unit Offering and Debenture Offering
Apr 23 / 2021

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list
Apr 23 / 2021

(German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
Apr 09 / 2021

Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
Apr 08 / 2021

(German Translation – April 8, 2021)
Apr 08 / 2021

Hemostemix Announces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets Ltd.
Mar 18 / 2021

Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to encrypt its Communications with Regulatory Authorities
Feb 11 / 2021

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
Jan 28 / 2021

HEMOSTEMIX ANNOUNCES HS 12 – 01 CLINICAL TRIAL COMPLETION OF SUBJECTS’ FOLLOW-UP VISITS AT THE END OF MARCH AND WARRANTS EXTENTED AND REPRICED
Jan 22 / 2021

HEMOSTEMIX ANNOUNCES THE BREAD CONTRACT WITH THE DEPARTMENT OF FOREIGN AFFAIRS, TRADE & DEVELOPMENT CANADA
Jan 04 / 2021

HEMOSTEMIX ANNOUNCES GRANT OF STOCK OPTIONS
Dec 31 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT
Dec 29 / 2020

HEMOSTEMIX ANNOUNCES PRIVATE PLACEMENT UPDATE
Dec 18 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF EXISTING PRIVATE PLACEMENT AND ANNOUNCES A NEW PRIVATE PLACEMENT
Dec 10 / 2020

HEMOSTEMIX ANNOUNCES ISSUANCE OF SHARES FOR DEBT
Nov 27 / 2020

Hemostemix Announces Possession of All Clinical Trial Data and $2,500,000 Unit Financing
Nov 25 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF PRIVATE PLACEMENT
Oct 08 / 2020

Hemostemix Announces Partial Win in Florida
Sep 29 / 2020

Hemostemix Announces Private Placement and Debt Settlement
Sep 23 / 2020

Hemostemix Announces Dr. Pierre Leimgruber as Interim Chief Medical Officer
Sep 22 / 2020

Hemostemix Provides Update on Litigation and Consolidation of its Common Shares
Jul 10 / 2020

Hemostemix Files its Audited Annual Financial Statements and Management Discussion and Analysis for the period ending December 31, 2019
Jul 06 / 2020

Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix’s Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Science
Jul 03 / 2020

HEMOSTEMIX PROVIDES UPDATE ON FILING Q1 FINANCIAL STATEMENTS
Jul 03 / 2020

Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Jun 30 / 2020

HEMOSTEMIX PROVIDES BI-WEEKLY UPDATE ON STATUS OF MANAGEMENT CEASE TRADE ORDER
Jun 24 / 2020

Hemostemix Appeals Alberta Court’s Service Ex Juris Decision
Jun 19 / 2020

Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC
Jun 18 / 2020

HEMOSTEMIX ANNOUNCES ISSUANCE OF MANAGEMENT CEASE TRADE ORDER BY ASC
Jun 16 / 2020

HEMOSTEMIX ANNOUNCES DELAY IN FILING OF ANNUAL FINANCIAL STATEMENTS AND APPLICATION FOR MANAGEMENT CEASE TRADE ORDER
Jun 08 / 2020

Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix’s Intellectual Property
Jun 03 / 2020

HEMOSTEMIX ANNOUNCES DR. MARY ARGENT-KATWALA AS ITS CLINICAL TRIAL MANAGER
Jun 03 / 2020

Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLC
May 28 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF PRIVATE PLACEMENT AND CORPORATE UPDATE
May 21 / 2020

Hemostemix Announces Corporate Update
May 19 / 2020

Hemostemix Announces Private Placement and Provides Debt Settlement Update
May 07 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF PRIVATE PLACEMENT
May 07 / 2020

HEMOSTEMIX ANNOUNCES ANNUAL SPECIAL MEETING RESULTS
Apr 30 / 2020

Hemostemix Announces the Appointment of David Tsubouchi to its Board of Advisors
Apr 29 / 2020

Hemostemix Announces Private Placement and Debt Settlement Update
Apr 22 / 2020

HEMOSTEMIX TO FOLLOW ALBERTA SECURITIES COMMISSION BLANKET ORDER 51-517
Apr 21 / 2020

HEMOSTEMIX ANNOUNCES THE APPOINTMENT OF TIMOTHY CHANG TO BOARD OF ADVISORS
Apr 20 / 2020

Hemostemix Announces Private Placement and Settlement of Debts
Apr 09 / 2020

HEMOSTEMIX ANNOUNCES THE APPOINTMENTS OF LORAN SWANBERG AND CHRISTINA WU, CPA, CGA
Apr 07 / 2020

HEMOSTEMIX APPOINTS THE HONOURABLE SHEILA COPPS, OC, PC, TO BOARD OF ADVISORS AND RATIFIES THOMAS SMEENK AS CHIEF EXECUTIVE OFFICER
Mar 26 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT
Mar 19 / 2020

HEMOSTEMIX ANNOUNCES PETER LACEY AS CHAIRMAN OF THE BOARD OF DIRECTORS
Mar 16 / 2020

HEMOSTEMIX ANNOUNCES DR. YORK HSIANG JOINS ITS SCIENTIFIC ADVISORY BOARD
Mar 16 / 2020

Hemostemix Announces the Passing of its Principal Founder, Roger Bergersen
Mar 10 / 2020

HEMOSTEMIX ANNOUNCES CORPORATE UPDATE
Mar 05 / 2020

HEMOSTEMIX ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT
Feb 28 / 2020

HEMOSTEMIX ANNOUNCES CORPORATE UPDATE
Feb 27 / 2020

HEMOSTEMIX ANNOUNCES CORPORATE UPDATE
Feb 25 / 2020

HEMOSTEMIX ANNOUNCES CORPORATE UPDATE
Feb 19 / 2020

HEMOSTEMIX ANNOUNCES FINANCING UPDATE AND SECURED CONVERTIBLE DEBENTURE FINANCING OF UP TO $2,000,000
Feb 10 / 2020

HEMOSTEMIX ANNOUNCES THE APPOINTMENT OF DR. RONNIE HERSHMAN TO THE BOARD OF DIRECTORS AND PROVIDES A CORPORATE UPDATE
Jan 26 / 2020

HEMOSTEMIX PROVIDES CORPORATE UPDATE AND CLARIFICATION
Jan 17 / 2020

HEMOSTEMIX ADDS THE 20th ACTIVE CLINICAL TRIAL SITE AND ENROLLS THE 56TH TRIAL SUBJECT
Jan 07 / 2020

HEMOSTEMIX ANNOUNCES 91st PATENT ISSUED and FINANCING UPDATE
Jan 02 / 2020

Hemostemix Announces Private Placement
Dec 11 / 2019

Hemostemix Announces Corporate Update
Dec 02 / 2019

Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting
Nov 29 / 2019

Hemostemix Announces Appointment of Director
Nov 22 / 2019

Hemostemix Announces Director Resignation
Nov 19 / 2019

Hemostemix Provides Corporate Update
Nov 08 / 2019

Notice of the Meeting and Record Date
Oct 31 / 2019

Hemostemix Provides Corporate Update
Oct 21 / 2019

Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
Oct 17 / 2019

Hemostemix Announces Commencement of Arbitration
Aug 28 / 2019

MD&A June 30, 2019
Aug 28 / 2019

Interim Financials to June 30, 2019
Aug 01 / 2019

Hemostemix Announces $2 Million Loan Facility
Jul 11 / 2019

Hemostemix Announces Financing Update and Interim CFO Appointment
Jul 02 / 2019

Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
Jun 27 / 2019

Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Jun 25 / 2019

Hemostemix Announces Resignation of CFO
May 29 / 2019

Financials Mar 31, 2019
May 29 / 2019

MD&A Mar 31, 2019
May 16 / 2019

Hemostemix Closes First Tranche of Financing
May 03 / 2019

Hemostemix Announces Convertible Debenture Financing
Apr 30 / 2019

Annual Financial Statements Dec 31, 2018
Apr 30 / 2019

MD&A Dec 31, 2018
Apr 15 / 2019

Hemostemix Announces Convertible Debenture Financing
Apr 10 / 2019

Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Apr 01 / 2019

Hemostemix Announces Appointment of Experienced Chief Medical Officer & President
Feb 25 / 2019

Hemostemix announces UC Davis Health added as a trial site for Phase II Clinical Trial
Feb 04 / 2019

Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
Jan 17 / 2019

Hemostemix Provides Highlights of 2018 Accomplishments
Jan 03 / 2019

Hemostemix Announces Two Additional Sites Enrolled in Phase II Clinical Trial
Nov 23 / 2018

MANAGEMENT’S DISCUSSION AND ANALYSIS
Nov 23 / 2018

Interim Condensed Consolidated Financial Statements
Nov 09 / 2018

Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
Nov 08 / 2018

Hemostemix Announces Important Manufacturing Process Refinements
Oct 30 / 2018

Hemostemix Announces OTCQB Listing and DTC Eligibility
Oct 09 / 2018

Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial
Sep 27 / 2018

Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
Sep 24 / 2018

Hemostemix Announces Addition to Its Clinical Trial Management Team
Aug 24 / 2018

Interim Condensed Consolidated Financial Statements
Aug 24 / 2018

Management’s Discussion and Analysis
Aug 16 / 2018

Hemostemix Announces Two New Strategic Trial Sites in Texas
Jul 18 / 2018

Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
Jul 05 / 2018

Hemostemix Formalizes World-Class Scientific Advisory Board
May 30 / 2018

Major Milestone Achieved With First 3 U.S. Trial Sites
May 28 / 2018

Management’s Discussion and Analysis
May 28 / 2018

Interim Condensed Consolidated Financial Statements
May 23 / 2018

Hemostemix Announces New EU Patent Grant
May 03 / 2018

Hemostemix Announces First Patient Treated in Phase II Clinical Trial
May 01 / 2018

MANAGEMENT’S DISCUSSION AND ANALYSIS
May 01 / 2018

Hemostemix Publishes 2017 Financials
Apr 27 / 2018

Hemostemix Announces Trial Site for Phase II Clinical Trial
Apr 19 / 2018

Hemostemix Announces US FDA Clinical Trial Approval
Feb 23 / 2018

Hemostemix Signs License Agreement with Aspire Health Science
Feb 22 / 2018

Hemostemix Signs Manufacturing Agreement with Aspire Health Science
Dec 20 / 2017

Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials
Nov 29 / 2017

MANAGEMENT’S DISCUSSION AND ANALYSIS
Nov 29 / 2017

Hemostemix Publishes Q3 2017 Financials
Sep 26 / 2017

Hemostemix Announces Agreement with CRO Service Provider Topstone Research
Sep 19 / 2017

ACQUISITION AND DISPOSITION OF SECURITIES OF HEMOSTEMIX INC.
Sep 15 / 2017

Hemostemix Completes Conversion of Subscription Receipts and Secured Credit Financing
Aug 29 / 2017

Hemostemix Publishes Q2 2017 Financials
Aug 29 / 2017

MANAGEMENT’S DISCUSSION AND ANALYSIS
Aug 25 / 2017

Hemostemix Completes Private Placement and Rights Offering
Aug 17 / 2017

Hemostemix Inc. Announces Agreement to Resolve all Outstanding Matters with Hemostemix (Asia) Corporation (HEMA)
Aug 15 / 2017

Hemostemix Announces Updates on Private Placement
Aug 15 / 2017

Hemostemix Announces Updates on Rights Offering
Jul 21 / 2017

Hemostemix Announces Updates on Rights Offering and Private Placement
Jul 11 / 2017

Hemostemix Announces Engagement of PI Financial Corp., Rights Offering and Updates on Proposed Private Placement and Senior Secured Credit Financing
Jun 30 / 2017

Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
Jun 09 / 2017

Hemostemix Inc. Announces Update on Status of Agreement with Hemostemix (Asia) Corporation (HEMA)
Jun 06 / 2017

Hemostemix Releases Management Information Circular
May 30 / 2017

MANAGEMENT’S DISCUSSION AND ANALYSIS
May 30 / 2017

Hemostemix Publishes Q1 2017 Financials
May 01 / 2017

MANAGEMENT’S DISCUSSION AND ANALYSIS
May 01 / 2017

Hemostemix Publishes 2016 Consolidated Financials
Apr 10 / 2017

Hemostemix Announces CDN$4,400,000 Senior Secured Debt Financing and Plans to Undertake a Private Placement for up to CDN$8,000,000
Mar 22 / 2017

Hemostemix Announces Corporate Updates
Feb 08 / 2017

Hemostemix Announces Further Progress and the Resumption of Trading
Jan 25 / 2017

Acquisition and Disposition of Securities of Hemostemix Inc.
Jan 25 / 2017

Acquisition and Disposition of Secorities of Hemostemix Inc.
Jan 25 / 2017

Hemostemix Announces Reorganization
Jan 06 / 2017

Hemostemix Announces Corporate Update
Jan 05 / 2017

Hemostemix Announces Corporate Update
Dec 22 / 2016

Hemostemix Announces Reorganization
Nov 29 / 2016

Hemostemix Publishes Q3 2016 Financials
Nov 02 / 2016

Early Warning Report Issued Pursuant to National Instrument 62-103
Oct 03 / 2016

Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada
Sep 22 / 2016

Hemostemix announces Offering
Sep 21 / 2016

Hemostemix Announces Successful Re-Certification of its Israeli Manufacturing Facility
Sep 09 / 2016

Hemostemix announces results of annual and special meeting
Sep 02 / 2016

Hemostemix Closes $1,644,000 Offering
Sep 01 / 2016

Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board
Aug 29 / 2016

Hemostemix Publishes Q2 2016 Financials
Aug 29 / 2016

Hemostemix Voids Taiwanese Agreement
Aug 11 / 2016

HEMOSTEMIX RAISES $ 1,610,000
Aug 09 / 2016

Hemostemix Announces Resignations
Aug 08 / 2016

Hemostemix Announces Adoption of Advance Notice By‐Law
Jun 28 / 2016

Hemostemix Announces Corporate Updates
May 30 / 2016

Hemostemix Publishes Q1 2016 Financials
May 20 / 2016

Hemostemix Announces Resignations
Apr 21 / 2016

Hemostemix Announces Non-Brokered Private Placement
Apr 18 / 2016

Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles
Mar 31 / 2016

Hemostemix Appoints Robert Achtymichuk as Vice President, Business Development
Mar 25 / 2016

Hemostemix Appoints Hardean E. Achneck, M.D. as Chief Medical Officer
Feb 03 / 2016

Hemostemix Issues Corporate Update From CEO Elmar Burchardt
Feb 03 / 2016

HEMOSTEMIX CONTINUES TO FOCUS ON BUILDING VALUE
Jan 21 / 2016

Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program
Jan 21 / 2016

Hemostemix to Present at Phacilitate Cell & Gene Therapy World 2016
Dec 28 / 2015

Hemostemix Joins the OTCQX Marketplace in the United States
Dec 22 / 2015

Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
Dec 02 / 2015

Hemostemix Announces Closing of the First Tranche of Brokered Private Placement
Dec 01 / 2015

Hemostemix Invited to Prestigious JP Morgan Conference
Nov 06 / 2015

Hemostemix Amends Terms of Private Placement
Oct 08 / 2015

Hemostemix Announces Brokered Private Placement
Oct 05 / 2015

Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa
Aug 20 / 2015

Hemostemix Holds First Meeting of Data Safety Monitoring Board (DSMB)
Aug 10 / 2015

Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States
Jul 27 / 2015

Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia
Jul 07 / 2015

Hemostemix Posts Corporate Presentation on Company Website
Jun 25 / 2015

Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia
Jun 18 / 2015

Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company’s ACP-01 Formulation to Treat Critical Limb Ischemia
Jun 17 / 2015

Hemostemix and Ludwig Boltzmann Institute for Experimental and Clinical Traumatology Enter Into Research Collaboration Agreement to Develop Hemostemix Regenerative Technology
Jun 16 / 2015

Hemostemix Inc. (the “Corporation”) (TSX-V: “HEM”) announced today the appointment of Rahul Sarugaser, PhD, to the position of vice president of business and corporate development.
Jun 15 / 2015

Hemostemix to Present in Italy at the 2015 Gordon Research Conference on Assisted Circulation
May 19 / 2015

Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia (CLI)
May 11 / 2015

Hemostemix Retains Stonegate Capital Partners for Investor Relations
Apr 20 / 2015

Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel
Mar 19 / 2015

Hemostemix Expands Clinical Trial for Critical Limb Ischemia (CLI) to Four Sites in South Africa, Treats First South African Participant
Mar 06 / 2015

Hemostemix Expands Clinical Trial For Treating Critical Limb Ischemia To The Peter Munk Cardiac Centre At Toronto General Hospital
Feb 02 / 2015

Hemostemix Names Dr. Hardean E. Achneck as Vice President of Clinical Research and Operations
Jan 28 / 2015

Hemostemix Names Gerald D. Brennan Jr. to Board of Directors; Announces Management Title Change
Jan 12 / 2015

Hemostemix Corporate Update
Nov 26 / 2014

Hemostemix and Technical Ventures Complete RTO Transaction
Oct 02 / 2014

Theravitae Inc. Announces Leadership Transition
Jun 25 / 2014

Hemostemix Advances Clinical Trial Preparation
May 05 / 2014

Hemostemix Joins Centre for Commercialization of Regenerative Medicine, Industry Consortium
Apr 22 / 2014

Hemostemix Announces its Second US Patent